Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GALR3 | O60755 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.33 |
| ▸ | RAF1 | P04049 | 1/20 | 0.33 |
| ▸ | BRAF | P15056 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.32 |
| ▸ | ITGAV | P06756 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5113619 | 0.86 | GCK (0.40) | KDRRAF1BRAFGCK | |
| SCHEMBL5101397 | 0.85 | KDR (0.36) | GALR3GAAMAOAMAOBKDR | |
| SCHEMBL5101212 | 0.83 | KDR (0.36) | GALR3GAAMAOAMAOBKDR | |
| SCHEMBL5102304 | 0.83 | RIPK1 (0.38) | KDRRIPK1 | |
| SCHEMBL5107763 | 0.82 | POLB (0.39) | GALR3GAARAF1BRAF | |
| SCHEMBL5115425 | 0.82 | HSD17B10 (0.41) | — | |
| SCHEMBL6375561 | 0.82 | KDR (0.35) | GALR3GAAMAOAMAOBKDR | |
| SCHEMBL5105614 | 0.82 | S1PR1 (0.43) | KDRITGB3ITGAV | |
| SCHEMBL5108320 | 0.82 | KDR (0.38) | KDRLNPEPITGB3ITGAV | |
| SCHEMBL5101380 | 0.81 | KDR (0.39) | KDRRAF1BRAFRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241038-A1 | Therapeutic agent for Abeta related disorders | EISAI CO., LTD. (JP) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241038-A1 | Therapeutic agent for Abeta related disorders | APP, BACE1, PSEN1 | GALR3 663/4885GAA 131/4885ROCK1 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.